Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Capita reaffirms outlook despite sales slide

(Sharecast News) - British outsourcing giant Capita reiterated its full-year guidance on Tuesday, despite seeing sales slide during the first half. The firm said adjusted revenues in the five months to 31 May were 4.5% lower.

Within that, public service revenues rose 2.3%, after growth in central government contracts helped offset previously announced losses in electronic monitoring.

But sales in the contact centre division slumped 21.1%, weighed down by subdued volumes in telecommunications, while pension solutions was 1.1% lower.

However, Capita said it remained confident of achieving full-year targets for broadly flat revenues and an improved operating margin, driven primarily by a £250m cost-cutting programme.

It continued: "We are on track to deliver the cost reduction programme by December 2025, and continue to expect the margin benefit to be weighted to the second half, reflecting the contact centre revenue reduction and cost pressures in the first half, driven by the timing of the group's pay review and additional National Insurance contributions."

Capita employs around 34,000 people, with clients in the UK and Europe.

The group also reiterated its commitment to using artificial intelligence more widely.

Adolfo Hernandez, chief executive, said: "In recent months, client interest in agentic AI solutions has grown exponentially. We are reinvesting a portion of our efficiency savings into new technology solutions, particularly those underpinned by AI."

As at 0930 BST shares in Capita were flat at 249.4p, having pared back earlier losses.

Robin Speakman, analyst at Shore Capital - which has a 'hold' rating on the stock - said: "While Capita continues to address its need to reduce operating costs, we note the challenges of pay awards and employment taxes, particularly in the UK, and remain cautious on the outcome through [the] 2025 and 2026 full years.

"We still see an encouraging at sales pipeline, though remain cautious on how government public spending plans pan out in actual contract volumes."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.